RINVOQ is licensed for the treatment of moderate-to-severe active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate. RINVOQ is also licensed for the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-UPAD-210377 | Date of preparation: March 2022
